Cell Line Development Services Global Market – Forecast to 2027

Publishing Date : January, 2019
Report Code : HCPH0112
Price:
Single license $4,950
Site license $6,750
Global license $9,000


Cell lines are one the major tools used in research for studying the normal physiology and biochemistry of cells, the effects of drugs and toxic compounds on the cells, drug screening and development and large scale manufacturing of biological compounds. Cell culture is the process by which cells are grown under controlled conditions derived from microbial or animal cells. Cell lines are subculture of primary culture also known as sub-clone. Cell lines derived from primary cultures have a limited life span, after subsequent cultures, cells with the highest growth capacity dominate which are selected for further cell development. Primary cells are cells that are cultured directly from a subject and have a limited lifespan. An immortalized cell line can proliferate indefinitely either through random mutation or deliberate modification which are useful especially for production of therapeutics.

The cell line development service market is expected to grow at double digit CAGR to reach $1,519.5 million by 2027. Increasing demand for biologics and biosimilars, growing incidence rate of oncology and immunological disorder and growth in research activities related to the diseases are driving the market. Technological improvements in development, manufacturing, screening technologies and assays are giving immense growth opportunity for the market. However, complexities in development of stable cell lines and high risk of contamination due to complex purification methods are restraining the market. Furthermore, stringent and complex regulations and high cost and technical requirement to adhere with accreditations such as GMP are posing threat to the industry.

Cell lines are essential for a wide range of applications including gene function studies, drug discovery assays, the production of biotherapeutics and diagnostics. The application for cell lines includes research, bioproduction and diagnostics. Among research, cell lines are used for studying disease, screening, cell-based assays are used during discovery phase and preclinical development. Cell lines are used to produce a wide range of biotherapeutics including vaccine, recombinant proteins that include peptides, cytokines, hormones and clotting factors, enzymes and monoclonal antibodies.

Biotherapeutics including monoclonal antibodies, peptides, recombinant proteins, vaccines, blood related products are produced in a wide variety of platforms, including non-mammalian expression systems (bacterial, yeast, plant and insect) and mammalian expression systems (including human cell lines).  However, the most appropriate expression system to be used is dependent on the type of biopharmaceutical to be produced. Microbial systems are used for producing relatively simple recombinant proteins such as insulin or antibody fragments. They are attractive due to their low cost and high productivity. E. coli and S. cerevisiae are the most commonly used systems. However, many biopharmaceuticals including MABs, highly glycosylated proteins or recombinant proteins are large and complex, mammalian cell lines are the most preferred platform used for manufacturing them.  Post-translational modifications including glycosylation, carboxylation, hydroxylation, sulphation, amidation are a significant factor to select the type of cells to be used. Among them, glycosylation is the most common modification. Mammalian expression system commanded the largest revenue of the global cell line development services market, by expression system in 2018. The most common mammalian cell cultures used for production of biopharmaceuticals include Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK21) cells and murine myeloma cells (NS0 and Sp2/0).

Among cell line type, CHO cell line is the most frequently used mammalian system, which is used in the manufacture of more than 57% of currently approved biologics. CHO cells have been the industry’s cell line workhorse for production of biopharmaceuticals. These cell line has several major advantages being versatile, relatively easy to work with, having well-understood glycosylation patterns. Approximately 36 monoclonal antibodies and 8 recombinant proteins are produced using CHO cell lines. Murine Myeloma are expected to occupy second largest share is expected to grow at a CAGR % from 2018 to 2027.

The increasing demand for biologics and biosimilars has increased the demand for production cell lines. The expiration of blockbuster biologics has also driven the emergence of biosimilars. Companies are working to produce efficient and less time consuming expression systems and also using automation and robotics in screening of cell lines to speed up the process. The SUREtechnology platform by Selexis S.A (Switzerland) has been able to generate stable and high performing cell lines in three months with productivity levels of 1-7 g/L for monoclonal antibodies and about 76 drugs in clinical phase and 3 marketed drugs have been developed.

Some of the major companies in the cell line development market include JSR Life Science (Selexis),  Lonza (Switzerland), Boehringer Ingelheim (Germany), Catalent (U.S.), Samsung Biologics (South Korea),  Fujifilm Diosynth (Japan) , Patheon (Thermo Fisher Scientific) (U.S.), AGC Biologics (U.S.), Merck KGaA (Germany), Rentschler Biotech (Germany), Genscript Biotech (China), Horizon Discovery (U.K.), Sartoris AG (France), Wuxi Apptec (China), and Eurofins (Luxembourg).

Some of the other players are Syngene (India), Evotec (Germany), Lake Pharma (U.S.), TCG Lifescience (India), Cobra Biologics (U.K.), Abzena (U.K.), JHL Biotech (Taiwan), Charles River Laboratories (U.S.), Mabplex (U.S.), Trenzyme (Germany), Atum (U.S.), ATCC (U.S.).

  • 1     EXECUTIVE SUMMARY
  • 2     MARKET DYNAMICS
    • 2.1     MARKET DYNAMICS
      • 2.1.1     DRIVERS AND OPPORTUNITIES
        • 2.1.1.1     GROWING INCIDENCE RATES OF ONCOLOGY AND IMMUNOLOGICAL DISORDERS AND INCREASING R&D ACTIVITIES RELATED TO THE DISEASES
        • 2.1.1.2     INCREASING DEMAND FOR BIOLOGICS AND BIOSIMILARS
        • 2.1.1.3     ADVANCED TECHNOLOGIES FOR SCREENING, CELL LINE ENGINEERING AND BIOPROCESSING
        • 2.1.1.4     INCREASING NUMBER OF CROS IN APAC REGIONS
      • 2.1.2     RESTRAINTS AND THREATS
        • 2.1.2.1     COMPLEXITIES IN DEVELOPMENT OF STABLE CELL LINES
        • 2.1.2.2     HIGH RISK OF CONTAMINATION DUE TO COMPLEX PURIFICATION METHOD
        • 2.1.2.3     STRINGENT AND COMPLEX REGULATIONS FOR BIOLOGICS IN NORTH AMERICA AND EUROPE
        • 2.1.2.4     HIGH COST AND TECHNICAL REQUIREMENTS TO OBTAIN GMP CERTIFICATIONS
  • 3     CELL LINE DEVELOPMENT
    • 3.1     CELL LINE CONSTRUCTION
    • 3.2     HOST CELL LINE ENGINEERING
    • 3.3     EXPRESSION SYSTEM
    • 3.4     TRANSIENT GENE EXPRESSION
    • 3.5     STABLE CELL LINE DEVELOPMENT
    • 3.6     SCREENING
    • 3.7     UPSTREAM PROCESS DEVELOPMENT
  • 4     HOST CELL LINES
    • 4.1     CELL LINE DEVELOPMENT SERVICES MARKET, BY EXPRESSION SYSTEM
      • 4.1.1     MICROBIAL EXPRESSION SYSTEMS
      • 4.1.2     MAMMALIAN EXPRESSION SYSTEM
      • 4.1.3     OTHERS
  • 5     CELL LINE DEVELOPMENT SERVICES, BY CELL TYPE
    • 5.1     INTRODUCTION
    • 5.2     CHO
    • 5.3     MOUSE MYELOMA
    • 5.4     BABY HAMSTER KIDNEY (BHK) CELLS
    • 5.5     HYBRIDOMA
    • 5.6     HUMAN EMBRYONIC KIDNEY (HEK) CELLS
    • 5.7     HUMAN EMBRYONIC RETINAL CELLS (PER.C6)
    • 5.8     OTHERS
  • 6     CELL LINE DEVELOPMENT SERVICES, BY APPLICATION
    • 6.1     RESEARCH
    • 6.2     BIOPRODUCTION
    • 6.3     DIAGNOSTICS
  • 7     KEY DEVELOPMENTS
  • 8     MARKET SHARE ANALYSIS
  • 9     COMPANY PROFILES
    • 9.1     AGC BIOLOGICS
      • 9.1.1     OVERVIEW
      • 9.1.2     FINANCIALS
      • 9.1.3     SERVICES
      • 9.1.4     KEY DEVELOPMENTS
      • 9.1.5     SWOT ANALYSIS
    • 9.2     BOEHRINGER INGELHEIM
      • 9.2.1     OVERVIEW
      • 9.2.2     FINANCIALS
      • 9.2.3     SERVICE PORTFOLIO
      • 9.2.4     KEY DEVELOPMENTS
      • 9.2.5     SWOT ANALYSIS
    • 9.3     CATALENT INC.
      • 9.3.1     OVERVIEW
      • 9.3.2     FINANCIALS
      • 9.3.3     SERVICE PORTFOLIO
      • 9.3.4     KEY DEVELOPMENTS
      • 9.3.5     SWOT ANALYSIS
    • 9.4     EUROFINS SCIENTIFIC GROUP
      • 9.4.1     OVERVIEW
      • 9.4.2     FINANCIALS
      • 9.4.3     SERVICES
      • 9.4.4     KEY DEVELOPMENTS
      • 9.4.5     SWOT ANALYSIS
      • 9.5.1     OVERVIEW
      • 9.5.2     FINANCIALS
      • 9.5.3     SERVICES
      • 9.5.4     KEY DEVELOPMENTS
      • 9.5.5     SWOT ANALYSIS
    • 9.6     GENSCRIPT BIOTECH CORPORATION
      • 9.6.1     OVERVIEW
      • 9.6.2     FINANCIALS
      • 9.6.3     SERVICE PORTFOLIO
      • 9.6.4     KEY DEVELOPMENTS
      • 9.6.5     SWOT ANALYSIS
    • 9.7     HORIZON DISCOVERY GROUP, PLC
      • 9.7.1     OVERVIEW
      • 9.7.2     FINANCIALS
      • 9.7.3     SERVICE PORTFOLIO
      • 9.7.4     KEY DEVELOPMENTS
      • 9.7.5     SWOT ANALYSIS
    • 9.8     JHL BIOTECH INC.
      • 9.8.1     OVERVIEW
      • 9.8.2     FINANCIALS
      • 9.8.3     SERVICE PORTFOLIO
      • 9.8.4     KEY DEVELOPMENTS
      • 9.8.5     SWOT ANALYSIS
    • 9.9     JSR LIFE SCIENCES (SELEXIS SA)
      • 9.9.1     OVERVIEW
      • 9.9.2     FINANCIALS
      • 9.9.3     SERVICE PORTFOLIO
      • 9.9.4     KEY DEVELOPMENTS
      • 9.9.5     SWOT ANALYSIS
    • 9.10     LONZA GROUP
      • 9.10.1     OVERVIEW
      • 9.10.2     FINANCIALS
      • 9.10.3     SERVICE PORTFOLIO
      • 9.10.4     KEY DEVELOPMENTS
      • 9.10.5     SWOT ANALYSIS
    • 9.11     MERCK KGAA
      • 9.11.1     OVERVIEW
      • 9.11.2     FINANCIALS
      • 9.11.3     PRODUCT PORTFOLIO
      • 9.11.4     KEY DEVELOPMENTS
      • 9.11.5     SWOT ANALYSIS
    • 9.12     RENTSCHLER BIOPHARMA SE
      • 9.12.1     OVERVIEW
      • 9.12.2     FINANCIALS
      • 9.12.3     SERVICES
      • 9.12.4     KEY DEVELOPMENTS
      • 9.12.5     SWOT ANALYSIS
    • 9.13     SAMSUNG BIOLOGICS
      • 9.13.1     OVERVIEW
      • 9.13.2     FINANCIALS
      • 9.13.3     SERVICE PORTFOLIO
      • 9.13.4     KEY DEVELOPMENTS
      • 9.13.5     SWOT ANALYSIS
    • 9.14     SARTORIUS AG
      • 9.14.1     OVERVIEW
      • 9.14.2     FINANCIALS
      • 9.14.3     SERVICES
      • 9.14.4     KEY DEVELOPMENTS
      • 9.14.5     SWOT ANALYSIS
    • 9.15     PATHEON (THERMO FISHER SCIENTIFIC)
      • 9.15.1     OVERVIEW
      • 9.15.2     FINANCIALS
      • 9.15.3     SERVICE PORTFOLIO
      • 9.15.4     KEY DEVELOPMENTS
      • 9.15.5     SWOT ANALYSIS
    • 9.16     WUXI BIOLOGICS (WUXI APPTEC)
      • 9.16.1     OVERVIEW
      • 9.16.2     FINANCIALS
      • 9.16.3     SERVICE PORTFOLIO
      • 9.16.4     KEY DEVELOPMENTS
      • 9.16.5     SWOT ANALYSIS

      LIST OF TABLES

      • TABLE 1     CELL LINE DEVELOPMENT SERVICES MARKET, BY REGION, (2017-2027) ($MN)
      • TABLE 2     APPROVED BIOLOGICS AND CELL LINE TYPE (2012-2018)
      • TABLE 3     NUMBER OF APPROVED BIOLOGICS BY CELL LINE TYPE (2012-2018)
      • TABLE 4     CELL LINE DEVELOPMENT SERVICES MARKET, BY EXPRESSION SYSTEM, (2017-2027) ($MN)
      • TABLE 5     CELL LINE DEVELOPMENT SERVICES MARKET, BY CELL TYPE, (2017-2027) ($MN)
      • TABLE 6     CELL LINE TYPE OF SOME APPROVED BIOLOGICS MODALITIES AND CELL LINE TYPE
      • TABLE 7     CELL LINE DEVELOPMENT SERVICES MARKET, BY APPLICATION, (2017-2027) ($MN)
      • TABLE 8     CELL LINE DEVELOPMENT TECHNOLOGIES
      • TABLE 9     CELL LINE DEVELOPMENT SERVICES COST
      • TABLE 10     KEY DEVELOPMENTS (2017-2018)
      • TABLE 11     COMPARISON MATRIX OF CELL LINE DEVELOPMENT PLAYERS AND SERVICES OFFERED
      • TABLE 12     AGC BIOLOGICS: TOTAL REVENUE AND R&D EXPENSES, (2016-2018(Q3)) ($MN)
      • TABLE 13     AGC BIOLOGCIS: TOTAL REVENUE, BY SEGMENTS, (2016-2018(Q3)) ($MN)
      • TABLE 14     BOEHRINGER INGELHEIM: TOTAL REVENUE AND R&D EXPENSES, (2015-2017) ($MN)
      • TABLE 15     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY SEGMENTS, (2015-2017) ($MN)
      • TABLE 16     BOEHRINGER INGELHEIM: TOTAL REVENUE, BY GEOGRAPHY, (2015-2017) ($MN)
      • TABLE 17     CATALENT INC: TOTAL REVENUE AND R&D EXPENSES (2016-2018) ($MN)
      • TABLE 18     CATALENT INC: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
      • TABLE 19     EUROFINS SCIENTIFIC GROUP: TOTAL REVENUE AND R&D EXPENSES, (2016-2018 (H1)) ($MN)
      • TABLE 20     EUROFINS SCIENTIFIC GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018 (H1)) ($MN)
      • TABLE 21     FUJIFILM HOLDINGS CORPORATION: TOTAL REVENUE AND R&D EXPENSES (2016-2018 (Q2)) ($MN)
      • TABLE 22     FUJIFILM HOLDINGS CORPORATION: TOTAL REVENUE, BY SEGMENTS (2016-2018 (Q2)) ($MN)
      • TABLE 23     FUJIFILM HOLDINGS CORPORATION: TOTAL REVENUE, BY REGION, (2016-2018 (Q2)) ($MN)
      • TABLE 24     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2016-2018(Q3)) ($MN)
      • TABLE 25     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY SEGMENTS, (2016-2018(Q3)) ($MN)
      • TABLE 26     GENSCRIPT BIOTECH CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018(Q3)) ($MN)
      • TABLE 27     HORIZON DISCOVERY GROUP: TOTAL REVENUE AND R&D EXPENSES, (2016-2018(H1)) ($MN)
      • TABLE 28     HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY SEGMENTS, (2016-2018(H1)) ($MN)
      • TABLE 29     HORIZON DISCOVERY GROUP: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018(H1)) ($MN)
      • TABLE 30     JHL BIOTECH: TOTAL REVENUE AND R & D EXPENSES (2015-2017) ($MN)
      • TABLE 31     LONZA GROUP: TOTAL REVENUE & R&D EXPENSES, (2016-2018 (H1)) ($MN)
      • TABLE 32     LONZA GROUP: TOTAL REVENUE, BY SEGMENT, (2016-2018(H1)) ($MN)
      • TABLE 33     LONZA GROUP: TOTAL REVENUE, BY GEOGRAPHY (2016-2018(H1)) ($MN)
      • TABLE 34     MERCK KGAA: TOTAL REVENUE AND R&D EXPENSES, (2016-2018(H1)) ($MN)
      • TABLE 35     MERCK KGAA: TOTAL REVENUE, BY SEGMENTS, (2016-2018(H1)) ($MN)
      • TABLE 36     MERCK KGAA: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018 (H1)) ($MN)
      • TABLE 37     SAMSUNG BIOLOGICS CO., LTD: TOTAL REVENUE & R&D EXPENSES, (2016-2018 (H1) ($MN)
      • TABLE 38     SAMSUNG BIOLOGICS: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018(H1)) ($MN)
      • TABLE 39     SARTORIUS AG: TOTAL REVENUE AND R&D EXPENSES, (2016-2018 (Q3)) ($MN)
      • TABLE 40     SARTORIUS AG: TOTAL REVENUE, BY SEGMENT, (2016-2018 (Q3)) ($MN)
      • TABLE 41     PATHEON (THERMO FISHER SCIENTIFIC): TOTAL REVENUE AND R&D EXPENSES (2016-2018 (Q3)) ($MN)
      • TABLE 42     PATHEON (THERMO FISHER SCIENTIFIC): TOTAL REVENUE, BY SEGMENT, (2016-2018(Q3)) ($MN)
      • TABLE 43     WUXI BIOLOGICS: TOTAL REVENUE AND R&D EXPENSES, (2016-2018(H1)) ($MN)

      LIST OF FIGURES

      • FIGURE 1     MARKET DYNAMICS OF CELL LINE DEVELOPMENT
      • FIGURE 2     CELL LINE DEVELOPMENT SERVICES MARKET, BY REGION, (2018 VS 2027) ($MN)
      • FIGURE 3     NUMBER OF APPROVED BIOLOGICS BY CELL LINE TYPE (2012-2018)
      • FIGURE 4     CELL LINE DEVELOPMENT SERVICES MARKET, BY EXPRESSION SYSTEM, (2018 V’S 2027) ($MN)
      • FIGURE 5     EXPRESSION SYSTEMS OF SOME APPROVED BIOLOGICS
      • FIGURE 6     CELL LINE DEVELOPMENT SERVICES MARKET, BY CELL TYPE, (2018 VS 2027) ($MN)
      • FIGURE 7     CELL LINE TYPE OF SOME APPROVED BIOLOGICS
      • FIGURE 8     CELL LINE TYPE OF SOME APPROVED BIOLOGICS MODALITIES AND CELL LINE TYPE
      • FIGURE 9     CELL LINE DEVELOPMENT SERVICES MARKET, BY APPLICATION, (2018 V’S 2027) ($MN)
      • FIGURE 10     KEY DEVELOPMENTS OF CELL LINE DEVELOPMENT MARKET PLAYERS, (2017-2018)
      • FIGURE 11     MARKET SHARE ANALYSIS, BY CELL LINE DEVELOPMENT MAJOR PLAYERS (2018)
      • FIGURE 12     OVERVIEW: AGC BIOLOGICS
      • FIGURE 13     SWOT: AGC BIOLOGICS
      • FIGURE 14     BOEHRINGER INGELHEIM REVENUE OVERVIEW
      • FIGURE 15     SWOT: BOEHRINGER INGELHEIM
      • FIGURE 16     OVERVIEW: CATALENT INC.
      • FIGURE 17     SWOT: CATALENT INC.
      • FIGURE 18     OVERVIEW: EUROFINS SCIENTIFIC GROUP
      • FIGURE 19     SWOT: EUROFINS SCIENTIFIC GROUP
      • FIGURE 20     SWOT: FUJIFILM DIOSYNTH BIOTECHNOLOGIES
      • FIGURE 21     OVERVIEW: GENSCRIPT BIOTECH CORPORATION
      • FIGURE 22     SWOT: GENSCRIPT BIOTECH CORPORATION
      • FIGURE 23     OVERVIEW: HORIZON DISCOVERY GROUP, PLC
      • FIGURE 24     SWOT: HORIZON DISCOVERY GROUP, PLC
      • FIGURE 25     OVERVIEW: JHL BIOTECH
      • FIGURE 26     SWOT: JHL BIOTECH INC.
      • FIGURE 27     SWOT: JSR LIFE SCIENCES (SELEXIS SA)
      • FIGURE 28     OVERVIEW: LONZA GROUP
      • FIGURE 29     SWOT: LONZA GROUP
      • FIGURE 30     OVERVIEW: MERCK KGAA
      • FIGURE 31     SWOT: MERCK KGAA
      • FIGURE 32     SWOT: RENTSCHLER BIOPHARMA SE
      • FIGURE 33     OVERVIEW: SAMSUNG BIOLOGICS
      • FIGURE 34     SWOT: SAMSUNG BIOLOGICS
      • FIGURE 35     OVERVIEW: SARTORIUS AG
      • FIGURE 36     SWOT: SARTORIUS AG
      • FIGURE 37     OVERVIEW: PATHEON (THERMO FISHER SCIENTIFIC)
      • FIGURE 38     SWOT: PATHEON (THERMO FISHER SCIENTIFIC)
      • FIGURE 39     SWOT: WUXI BIOLOGICS

      LIST OF COMPANIES MENTIONED IN THE REPORT

      • 1     AMGEN
      • 2     ABEOMICS
      • 3     ABGENEX
      • 4     ABZENA
      • 5     ABMGOOD
      • 6     ACRO BIOSYSTEMS
      • 7     AMPLYCELL
      • 8     APPLIED STEM CELL
      • 9     ARAGEN (GVK)
      • 10     ATCC
      • 11     ATUM
      • 12     BOEHRINGER INGELHEIM
      • 13     BPS BIOSCIENCE
      • 14     C & M BIOLABS
      • 15     CATALENT
      • 16     CELLOMICS TECHNOLOGY
      • 17     CELONIC
      • 18     CEVEC PHARMACEUTICALS GMBH
      • 19     CHARLES RIVER LABORATORIES
      • 20     CHROMOS MOLECULAR SYSTEMS
      • 21     COBRA BIOLOGICS
      • 22     CREATIVE BIOLABS
      • 23     CRUCELL (JANSSEN, J&J)
      • 24     CROWN BIOSCIENCE (JSR CORPORATION)
      • 25     CYTOVANCE BIOLOGICS
      • 26     EUROFINS
      • 27     EVOTEC
      • 28     EXONBIO
      • 29     FUJIFILM DIOSYNTH BIOTECHNOLOGIES
      • 30     FUSION ANTIBODIES
      • 31     G&P BIOSCIENCES
      • 32     GEN TARGET
      • 33     GENSCRIPT
      • 34     GLYCOTOPE
      • 35     GOODWINBIOTECHNOLOGY
      • 36     HORIZON DISCOVERY
      • 37     JHL BIOTECH
      • 38     KBI BIOPHARMA (JSR CORPORATION)
      • 39     LAKEPHARMA
      • 40     LFB BIOMANUFACTURING
      • 41     LONZA
      • 42     MABPLEX
      • 43     MERCK KGAA
      • 44     OXFORD GENETICS
      • 45     PATHEON (THERMO FISHER SCIENTIFIC)
      • 46     PRECISION ANTIBODY
      • 47     PROBIOGEN
      • 48     PROFACGEN
      • 49     RENTSCHLER BIOTECH
      • 50     SARTORIUS STEDIM BIOTECH S.A.
      • 51     SELEXIS S.A. (JSR CORPORATION)
      • 52     SGI-DNA
      • 53     SHANGHAI CHEMPARTNER
      • 54     SHANGHAI MEDICILON
      • 55     SINO BIOLOGICAL
      • 56     SPEED BIOSYSTEM
      • 57     SYDLABS
      • 58     SYNGENE
      • 59     TCG LIFESCIENCES
      • 60     TEXCELL
      • 61     TRENZYME
      • 62     UGA BIOPHARMA
      • 63     WUXI APPTEC